Multinational biotech firm HiFiBiO Therapeutics has agreed a multi-target deal with Japan’s Takeda Pharmaceutical (TYO: 4502) to try to discover breakthrough antibody therapies in gastroenterology and oncology.
The firms will work together to discover antibodies against targets chosen by Takeda. Takeda will be responsible for further preclinical and clinical development.
HiFiBiO, which is focused on using single-B-cell screening and analysis, will receive upfront, R&D, milestone, and royalty payments. Further financial terms were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze